IP Library › Granted Patent US 12,384,811
Granted Patent B2
US 12,384,811 · App. 17/598,064 · Granted Aug 12, 2025

Sialidase-resistant saccharide and method of making and using the same

Inventors: Chi-Huey Wong (Rancho Santa Fe, CA); Hong-Jay Lo (New Taipei, TW)
Assignee: Academia Sinica
C07H15/18C07H1/00C07K16/283C07K16/2887C07K2317/24C07K2317/41C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,384,811
App. No.
17/598,064
Granted
Aug 12, 2025
Kind
B2
Abstract

Disclosed are a method of preparing a saccharide that contains a 3-fluoro-sialic acid and a method of bonding it to a homogeneous antibody. Also within the scope of this invention are compounds each containing a 3-fluoro-sialic acid, monoclonal antibodies bonded to α2,6-linked 3-fluoro-sialo-side terminated N-glycans, and treatment of cancer with such monoclonal antibodies.

Claims (17)

1. A method of preparing a saccharide containing a 3-fluoro-sialic acid, the method comprising:

conducting a glycosylation reaction by reacting a 3-hydroxy-sialic acid with a saccharide to form an α2,6-linked 3-hydroxy-sialoside, wherein:

the 3-hydroxy-sialic acid is of formula (I):

the saccharide is a compound of formula (II):

and

the α2,6-linked 3-hydroxy-sialoside is a compound of formula (III):

and

conducting a fluorination reaction by reacting the α2,6-linked 3-hydroxy-sialoside with a fluorinating agent to form a saccharide containing a 3-fluoro-sialic acid, wherein the saccharide containing a 3-fluoro-sialic acid is a compound of formula (IV):

2. The method of claim 1 , wherein the fluorinating agent is perfluoro-1-butanesulfonyl fluoride (NfF), and the fluorination reaction is conducted in the presence of a catalyst, wherein the catalyst is 1,8-diazabicyclo[5,4,0]-undec-7-ene (DBU) and the fluorination reaction is optionally conducted in toluene, wherein the fluorination reaction is conducted further in the presence of tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF).

3. The method of claim 1 , wherein the fluorinating agent is NfF, the glycosylation reaction is conducted in the presence of AgOTf and Na 2 HPO 4 , and the fluorination reaction is conducted in the presence of a catalyst.

4. The method of claim 3 , wherein the catalyst is DBU and each of the glycosylation and fluorination reactions is conducted in toluene and wherein the fluorination reaction is conducted further in the presence of TASF.

5. The method of claim 1 , further comprising conducting another glycosylation reaction by reacting the saccharide containing a 3-fluoro-sialic acid with a second saccharide, wherein the fluorinating agent is NfF, the glycosylation reaction is conducted in the presence of AgOTf and Na 2 HPO 4 , and the fluorination reaction is conducted in the presence of a catalyst; wherein the catalyst is DBU and each of the glycosylation and fluorination reactions is conducted in toluene, and wherein the fluorination reaction is optionally conducted further in the presence of TASF.

6. A method of preparing a homogeneous antibody bonded to a saccharide containing a 3-fluoro-sialic acid, comprising:

preparing a saccharide containing a 3-fluoro-sialic acid according to claim 1 ; and

glycosylating a monoclonal antibody with said saccharide containing a 3-fluoro-sialic acid.

7. The method of claim 6 , wherein the fluorinating agent is NfF, the glycosylation reaction is conducted in the presence of AgOTf and Na 2 HPO 4 , and the fluorination reaction is conducted in the presence of a catalyst, wherein the catalyst is DBU and each of the glycosylation and fluorination reactions is conducted in toluene, and

optionally further comprising after the fluorination reaction, conducting another glycosylation reaction by reacting the saccharide containing a 3-fluoro-sialic acid with a second saccharide.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded Feb 21, 2023
From: WONG, CHI-HUEY; LO, HONG-JAY
To: ACADEMIA SINICA
Reel/Frame 062757/0450 →
Continuity (2)
Provisional Application 62829736 · Apr 5, 2019
Related Publication 20220267363A1 · Aug 25, 2022
References Cited (228)
US 7871626B2 · Hoffmann et al. · 2011 [cited by applicant]
US 10301377B2 · Graham et al. · 2019 [cited by applicant]
US 10906944B2 · He et al. · 2021 [cited by applicant]
US 10953089B1 · Smith et al. · 2021 [cited by applicant]
US 10954289B1 · Babb et al. · 2021 [cited by applicant]
US 11480391B2 · Wong et al. · 2022 [cited by applicant]
US 11866485B2 · Lin et al. · 2024 [cited by applicant]
US 11918641B2 · Wong · 2024 [cited by applicant]
US 11992525B2 · Wong et al. · 2024 [cited by applicant]
US 12085340B2 · Wong et al. · 2024 [cited by applicant]
US 20060073542A1 · Bayer et al. · 2006 [cited by applicant]
US 20100041740A1 · Wong et al. · 2010 [cited by applicant]
US 20100247571A1 · Wong et al. · 2010 [cited by applicant]
US 20130309176A1 · Port et al. · 2013 [cited by applicant]
US 20140107049A1 · Bennani et al. · 2014 [cited by applicant]
US 20150132330A1 · Garcia-Sastre et al. · 2015 [cited by applicant]
US 20160199481A1 · Bloom · 2016 [cited by applicant]
US 20160376321A1 · Hotez et al. · 2016 [cited by applicant]
US 20180043007A1 · LeFebvre et al. · 2018 [cited by applicant]
US 20190388460A1 · Hedrick et al. · 2019 [cited by applicant]
US 20200046826A1 · Wong et al. · 2020 [cited by applicant]
US 20200078452A1 · Wong et al. · 2020 [cited by applicant]
US 20200079808A1 · Pfister et al. · 2020 [cited by applicant]
US 20200231633A1 · Berman et al. · 2020 [cited by applicant]
US 20200283743A1 · Zhang et al. · 2020 [cited by applicant]
US 20210017563A1 · Bhatnagar et al. · 2021 [cited by applicant]
US 20210207106A1 · Anthony et al. · 2021 [cited by applicant]
US 20210316002A1 · Ellis · 2021 [cited by applicant]
US 20220233713A1 · Callan et al. · 2022 [cited by applicant]
US 20230000741A1 · Wong et al. · 2023 [cited by applicant]
US 20230074185A1 · Wong et al. · 2023 [cited by applicant]
US 20230105209A1 · Lin et al. · 2023 [cited by applicant]
US 20230002790A1 · Lin et al. · 2023 [cited by applicant]
US 20230279080A1 · Lin et al. · 2023 [cited by applicant]
US 20240016917A1 · Ma et al. · 2024 [cited by applicant]
US 20240066113A1 · Wong et al. · 2024 [cited by applicant]
US 20240100147A1 · Wong et al. · 2024 [cited by applicant]
US 20240228591A1 · Lin et al. · 2024 [cited by applicant]
US 20240366516A1 · Wong et al. · 2024 [cited by applicant]
US 20240366517A1 · Wong et al. · 2024 [cited by applicant]
US 20240384320A1 · Wong et al. · 2024 [cited by applicant]
US 20250041222A1 · Wong et al. · 2025 [cited by applicant]
CN 105934441A · 2016 [cited by applicant]
CN 112626124A · 2021 [cited by applicant]
CN 116478948A · 2023 [cited by applicant]
EP 1987068A1 · 2008 [cited by applicant]
EP 2949665A1 · 2015 [cited by applicant]
JP 2012530499A · 2012 [cited by applicant]
JP 2017518989A · 2017 [cited by applicant]
RU 2720614C1 · 2020 [cited by applicant]
RU 2730897C1 · 2020 [cited by applicant]
WO 2004099240A2 · 2004 [cited by applicant]
WO 2004099240A3 · 2004 [cited by applicant]
WO 2007008918A2 · 2007 [cited by applicant]
WO 2007095506A1 · 2007 [cited by applicant]
WO 2009002516A1 · 2008 [cited by applicant]
WO 2009007427A2 · 2009 [cited by applicant]
WO 2010022737A1 · 2010 [cited by applicant]
WO 2010111687A2 · 2010 [cited by applicant]
WO 2010148511A1 · 2010 [cited by applicant]
WO 2011115862A1 · 2011 [cited by applicant]
WO 2012054907A2 · 2012 [cited by applicant]
WO 2012088428A1 · 2012 [cited by applicant]
WO 2013043729A1 · 2013 [cited by applicant]
WO 2013067652A1 · 2013 [cited by applicant]
WO 2014115797A1 · 2014 [cited by applicant]
WO 2015057942A1 · 2015 [cited by applicant]
WO 2015073727A1 · 2015 [cited by applicant]
WO 2015176662A1 · 2015 [cited by applicant]
WO WO2015184004A1 · 2015 [cited by applicant]
WO 2017062496A2 · 2017 [cited by applicant]
WO WO2017081082A2 · 2017 [cited by applicant]
WO 2018089407 · 2017 [cited by applicant]
WO 2018089407A1 · 2018 [cited by applicant]
WO 2019028190A1 · 2019 [cited by applicant]
WO 2015028478A1 · 2019 [cited by applicant]
WO 2019246363A1 · 2019 [cited by applicant]
WO 2020011275A1 · 2020 [cited by applicant]
WO 2020058239A1 · 2020 [cited by applicant]
WO WO2020205034 · 2020 [cited by applicant]
WO 2019246363 · 2020 [cited by applicant]
WO 2020172072A1 · 2020 [cited by applicant]
WO 2020198865A1 · 2020 [cited by applicant]
WO 2021019102A2 · 2021 [cited by applicant]
WO 2021035325A1 · 2021 [cited by applicant]
WO 2021045632A1 · 2021 [cited by applicant]
WO 2021045836A1 · 2021 [cited by applicant]
WO 2021226533 · 2021 [cited by applicant]
WO 2021174128A1 · 2021 [cited by applicant]
WO 2021180602A1 · 2021 [cited by applicant]
WO 2021183195A1 · 2021 [cited by applicant]
WO 2021186028A1 · 2021 [cited by applicant]
WO 2021214204A1 · 2021 [cited by applicant]
WO 2021219897A1 · 2021 [cited by applicant]
WO 2021233989A1 · 2021 [cited by applicant]
WO 2021257586A1 · 2021 [cited by applicant]
WO 2022047401A1 · 2022 [cited by applicant]
WO 2022221835 · 2022 [cited by applicant]
WO 2022221837 · 2022 [cited by applicant]
WO 2022221835A2 · 2022 [cited by applicant]
WO 2023056482 · 2022 [cited by applicant]
WO 2022227927A1 · 2022 [cited by applicant]
WO 2022229854A1 · 2022 [cited by applicant]
WO 2023129928 · 2022 [cited by applicant]
WO 2023021111A1 · 2023 [cited by applicant]
WO 2023056482A1 · 2023 [cited by applicant]
WO 2023069551A1 · 2023 [cited by applicant]
WO 2023129928A2 · 2023 [cited by applicant]
WO 2024215614A2 · 2024 [cited by applicant]
WO 2024215616A2 · 2024 [cited by applicant]
WO PCTUS2460715 · 2024 [cited by applicant]
Okamoto, K. et al. Tetrahedron Letters, 1986, vol. 27, No. 43, pp. 5233-5236 (Year: 1986). [cited by examiner]
Chokhawala, H. A. et al. J. Am. Chem. Soc., 2007, vol. 129, No. 35, pp. 10630-10631 (Year: 2007). [cited by examiner]
Kurzawa, Synlett 2015, 26, 1422-1423 (Year: 2015). [cited by examiner]
Doboszewski et al., 1987, Canadian Journal of Chemistry. 65(2): 412-419 (Year: 1987). [cited by examiner]
Bennua-Skalmowski et al., Tetrahedron Letters, vol. 36, No. 15, pp. 2611-2614, 1995 (Year: 1995). [cited by examiner]
Lo et al., J. Am. Chem. Soc. 2019, 141, 6484-6488 (Year: 2019). [cited by examiner]
Chokhawala et al “Enzymatic Synthesis of Fluorinated Mechanistic Probes for Sialidases and Sialyltransferases” Journal of the American Chemical Society vol. 129, pp. 10630-10631, 2007. [cited by applicant]
Hayashi et al “Stereospecific a-Sialylation by Site-Selective Fluorination” Angewandte Chemie International Edition vol. 58, pp. 3814-3818, 2019. [cited by applicant]
Lo et al “Synthesis of Sialidase-Resistant Oligosaccharide and Antibody Glycoform Containing α2,6-Linked 3F [cited by applicant]
Okamoto et al “An Effective Synthesis of α-Glycosides of N-Acetylneuraminic Acid by Use of 2β-Halo-3β-Hydroxy-4,7,8,9-Tetra- [cited by applicant]
Castrucci, M.R. et al., “Biologic importance of neuramindase stalk length in influenza A virus”, Journal of Virology, 1993, vol. 67, No. 2, pp. 759-764. [cited by applicant]
Dowling, W. et al., “Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines”, J. of Virology, 2007, vol. 81, No. 4, pp. 1821-1837, p. 1822, second column, fou… [cited by applicant]
Feng et al., “A Glycolipid Adjuvant, 7DW8-5, Enhances the Protective Immune Response to the Current Slpit Influenza Vaccine in Mice”, Frontiers in Microbiology, Sep. 18, 2019, vol. 10, No. 2157M, pp. 1-9; abstract. [cited by applicant]
Galili, “Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present alpha-gal epitopes”, Vaccine, Aug. 19, 2020; abstract; Fig. 1; DOI: 10.1016/j.vaccine.2020… [cited by applicant]
GenBank Accession CCH23214, haemagglutinin [Influenza A virus (A/WSN/1933(H1N1))], 2013. [cited by applicant]
GenBank Accession, ACF54601, neuraminidase [Influenza A virus (A/WSN/1933(H1N1))], 2008. [cited by applicant]
Gillian, M. Air, “Influenza neuraminidase”, Influenza and Other Respiratory Viruses, 2011. [cited by applicant]
Hughes et al., “Adaptation of Influenza A Viruses to Cells Expressing Low Levels of Sialic Acid Leads to Loss of Neuraminidase Activity”, Journal of Virology, 2001, vol. 75, No. 8, pp. 3766-3770. [cited by applicant]
Li, et al., Glycosylation of Neuraminidase Determines the Neurovirulence of Influenza A/WSN/33 Virus, 1993, Journal of Virology, vol. 67, No. 11, pp. 6667-6673. [cited by applicant]
Liu, Wen-Chun et al., “Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design”, Journal of Virology, vol. 90 No. 19, Oct. 20… [cited by applicant]
Medina, Rafael A. et al., “Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses”, Sci Transl Med., May 29, 2013. [cited by applicant]
Nobusawa et al., “Comparison of Complete Amino Acid Sequences and Receptor-Binding Properties among 13 Serotypes of Hemagglutinins of Influenza A Viruses”, Virology, 182, 475-485 (1991). [cited by applicant]
Rahman, M Shaminur et al., “Epitope-based chimeric peptide vaccine design against S, M, and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic, an in silico approach”, PeerJ, Jul. 27, 2020 (publication d… [cited by applicant]
Roberts, Paul C. et al., “Role of Conserved Glycosylation Sites in Maturation and Transport of Influenza A Virus Hemagglutinin”, Journal of Virology, Jun. 1993, p. 3048-3060. [cited by applicant]
Sun et al., “N-Linked Glycosylation of the Hemagglutinin Protein Influences Virulence and Antigenicity of the 1918 Pandemic and Seasonal H1N1 Influenza A Viruses”, 2013, Journal of Virology, vol. 87, No. 15, pp. 8756-87… [cited by applicant]
Wu, Chung-Yi et al., “Influenza A surface glycosylation and vaccine design”, PNAS, Jan. 2017, (Epub Dec. 27, 2016), vol. 114, No. 2, pp. 280-285. [cited by applicant]
Yang, Zhiwei et al., “Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study”, J Comput Aided Mol Des, 27: 935-950, 2013. [cited by applicant]
Zaraket, Hassan et al., “Full Genome Characterization of Human Influenza A/H3N2 Isolates from Asian Countries Reveals a Rare Amantadine Resistance-Conferring Mutation and Novel PB1-F2 Polymorphisms”, Frontiers in Microb… [cited by applicant]
Zhang, Xiaojian et al., “Role of stem glycans attached haemagglutinin in the biological characteristics of H5N1 avian influenza virus”, Journal of General Virology, 96, 1248-1257, 2015. [cited by applicant]
Zhang, Yan et al., “Glycosylation on Hemagglutinin Affects the Virulence and Pathogenicity of Pandemic H1N1/2009 Influenza A Virus in Mice”, PLOS One, vol. 8, Issue 4, Apr. 2013. [cited by applicant]
Zhao, “Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production”, Frontiers in Molecular Biosciences, Apr. 13, 2021; Entire Document; DOI: 10.3389/fmolb.2021.629873. [cited by applicant]
Zheng, J. et al., “Identification of N-linked glycosylation sites in the spike protein and their functional impact on the replication and infectivity of coronavirus infectious bronchitis virus in cell culture”, Virology… [cited by applicant]
Davies, Nicholas G. et al., “Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England,” Science, Apr. 2021, vol. 372, pp. 149 (10 pages). [cited by applicant]
Focosi, Daniele, “Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines,” Rev. Med Virol., 2021, vol. 31, 21 pp. e2231. [cited by applicant]
GenBank accession MN908947.3, Mar. 18, 2020, 11 pages. (https://www.ncbi.nlm.nih.gov/nuccore/MN908947). [cited by applicant]
Magazine, Nicholas et al., “Mutations and Evolution of the SARS-COV-2 Spike Protein,” Viruses, 2022, vol. 14, 640, 11 pgs. [cited by applicant]
Office Action and Search Report issued in Taiwan Patent Application No. 111113933 on Mar. 26, 2024. English translation of search report. [cited by applicant]
Watanabe, Yasunori et al., “Site-specific glycan analysis of the SARS-CoV-2 spike,” Science, Jul. 2020, vol. 369, pp. 330-333. [cited by applicant]
Bosch, Berend Jan et al.,“Coronavirus Escape from Heptad Repeat 2 (HR2)-Derived Peptide Entry Inhibition as a Result of Mutations in the HR1 Domain of the Spike Fusion Protein,” J of Virol., Mar. 2008, vol. 82, No. 5, p… [cited by applicant]
Galili, Uri, “Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present [alpha]-gal epitopes,” Vaccine, 2020, vol. 38, pp. 6487-6499. [cited by applicant]
GenBank Accession BCN86353.1 accessed on Jan. 22, 2021. https://www.ncbi.nlm.nih.gov/protein/BCN86353.1?report=genbank&log$=protalign&blast_rank=2&RID=EYKWWEAA016. [cited by applicant]
GenBank: QLB39105.1 accessed on Jan. 1, 2020. https://www.ncbi.nlm.nih.gov/protein/QLB39105.1?report=genbank&log$=protalign&blast_rank=1&RID=EYKWWEAA016. [cited by applicant]
GenBank: QTA38985.1 accessed Mar. 21, 2021. https://www.ncbi.nlm.nih.gov/protein/QTA38985.1?report=genbank&log$=protalign&blast_rank=3&RID=EYKWWEAA016. [cited by applicant]
International Search Report and Written Opinion issued on Jun. 22, 2023 in International Patent Application No. PCT/US22/82428. [cited by applicant]
Official Action, dated Aug. 31, 2023, received in Russia Patent Application No. 2023100504. English translation provided. [cited by applicant]
Search Report, dated Aug. 31, 2023, received in Russia Patent Application No. 2023100504. [cited by applicant]
Tai, Wanbo et al., “Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine,” Cell Mol Immunol. Jun. 2020;1… [cited by applicant]
Tian, Jing-Hui et al., “SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice,” Nature Communications, 2021, 14 pages. Downloaded Sep. 27, 2023: https://doi.org/10.… [cited by applicant]
Weissman, Drew et al., “D614G Spike Mutation Increases Sars CoV-2 Susceptibility to Neutralization,” Cell Host & Microbe, Jan. 13, 2021, vol. 29, pp. 23-31 (e1-e4). [cited by applicant]
Bernstein, David et al., “Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomized, placebo-controlled, phase 1 clinical trial”, The Lancet Infectiou… [cited by applicant]
Galili, Uri, “COVID-19 variants as moving targets and how to sop them by glycoengineered whole-virus vaccines,” Virulence, 12:1, 1717-1720, DOI:10.1080/21505594.2021.1939924. (https://doi.org/10.1080/21505594.2021.19399… [cited by applicant]
GenBank Accession: QHD43416.1, (Mar. 18, 2020) [Described in the Office Action as Appendix A] (Year: 2020). [cited by applicant]
Huang et al., “Impact of glycosylation on SARS-CoV-2 infection and broadly protective vaccine design,” BioRxiv, May 25, 2021, DOI: https://doi.org/10.1101/2021.05.25.445523, internal pp. 1-48. [cited by applicant]
Watanabe, Yasunori et al., “Exploitation of glycosylation in enveloped virus pathobiology,” BBA—General Subjects 1863, 2019), pp. 1480-1497. [cited by applicant]
Cao, Yiwei et al., “Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies,” JCTC, Sep. 16, 2021, vol. 17, pp. 6559-6569. [cited by applicant]
Edwards, et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” J. Mol. Biol., Nov. 2003, 14:334(1):103-18; doi: 10.1016/jmb… [cited by applicant]
Goel, Manisha et al., “Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response,” J. Immunol., Dec. 15, 2004, 173(12):7358-67 PMID: 15585860 DOI: 10.4049/jimmunol.173… [cited by applicant]
Janeway Jr., Charles A et al., “Immunobiology: The Immune System in Health and Disease,” 3rd edition, Garland Publishing Inc., 1997, pp. 3:1-3:11. [cited by applicant]
Kanyavuz, Alexia et al., “Breaking the law: unconventional strategies for antibody diversification,” Nat Rev Immunol., Jun. 2019, 19(6):355-368. doi:10.1038/S41577-019-0126-7. PMID: 30718829. [cited by applicant]
Lescar et al., “Crystal Structure of a Cross-reaction Complex between Fab F9.13.7 and Guinea Fowl Lysozyme,” J Biol Chem., Jul. 1995, 270(30):18067-76. doi: 10.1074/jbc.270.30.18067. PMID: 7629116. [cited by applicant]
Lloyd, C. et al., “Modelling the human immune response: performance of a 10(11) human antibody repertoire against a broad panel of therapeutically relevant antigens,” Protein Engineering Design & Selection, 2009, vol. 2… [cited by applicant]
Non-Final Office Action issued in U.S. Appl. No. 17/937,744 dated Jul. 5, 2023. [cited by applicant]
Rees-Spear, Chloe et al., “The effect of spike mutations on SARS-CoV-2 neutralization,” Cell Rep., Mar. 2023, 34 (12): 108890. Published online Mar. 6, 2021. doi: 10.1016/j.celrep.2021.108890: 10.1016/j.celrep.2021.1088… [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl Acad Sci U S A, Mar. 1982, vol. 79(6), pp. 1979-1983. doi: 10.1073/pnas.79.6.1979. PC/D: 6804947. [cited by applicant]
U.S. Appl. No. 17/598,064, filed Sep. 24, 2021, Chi-Huey Wong. [cited by applicant]
U.S. Appl. No. 18/029,758, filed Mar. 31, 2023, Chi-Huey Wong. [cited by applicant]
U.S. Appl. No. 18/501,578, filed Nov. 3, 2023, Chi-Huey Wong. [cited by applicant]
U.S. Appl. No. 63/266,008, filed Dec. 27, 2021, Kuo-I Lin. [cited by applicant]
U.S. Appl. No. 63/458,102, filed Apr. 8, 2023, Chi-Huey Wong. [cited by applicant]
U.S. Appl. No. 63/581,389, filed Sep. 8, 2023, Chi-Huey Wong. [cited by applicant]
Dang, Juanjuan et al., “Multivalency-assisted membrane-penetrating siRNA delivery sensitizes photothermal ablation via inhibition of tumor glycolysis metabolism,” Biomaterials, vol. 223, Dec. 2019, 119463. [cited by applicant]
Lostalé-Seijo, Irene and Montenegro, Javier, “Synthetic materials at the forefront of gene delivery,” Nature Reviews Chemistry, vol. 2, Sep. 21, 2018, pp. 258-277. [cited by applicant]
Office Action issued in Taiwan Patent Application No. 111113932 on Oct. 16, 2023. [cited by applicant]
Office Action issued on Nov. 14, 2022, in Israel Patent Application No. 293502. [cited by applicant]
Sanda, Miloslav et al., “N- and O-Glycosylation of the SARS-CoV-2 Spike Protein,” Anal. Chem., vol. 93, No. 4, Jan. 7, 2021, pp. 2003-2009. [cited by applicant]
Torres-Vanegas, Julian D., “Delivery Systems for Nucleic Acids and Proteins: Barriers, Cell Capture Pathways and Nanocarriers,” Pharmaceutics, vol. 13, No. 3, Mar. 22, 2021, pp. 428. [cited by applicant]
Vogel, Annette B. et al. “ BNT162b vaccines protect rhesus macaques from SARS-CoV-2,” Nature, vol. 592, Feb. 1, 2021, pp. 283-289. [cited by applicant]
Alam, MM et al., “Glycan-Modified Virus-Like Particles Evoke T Helper Type 1-Like Immune Responses,” ACS Nano, vol. 15, No. 1, Jan. 26, 2021, published online Aug. 17, 2020, doi: 10.1021/acsnano.0c03023, pp. 309-321; (p… [cited by applicant]
Avinash, MB et al., “Nanoarchitectonics of biomolecular assemblies for functional applications,” Nanoscale, vol. 6, No. 22, Nov. 21, 2014, doi: 10.1039/c4nr04340e, pp. 13348-13369. (p. 18, figure 13c). [cited by applicant]
Bej, Raju et al., “Disulfide chemistry in responsive aggregation of amphiphilic systems,” Royal Society of Chemistry, 2020, vol. 16, pp. 11-26. DOI: 10.1039/C9SM01960J. [cited by applicant]
Bellato, Frederica, “Targeting dendritic cells with mannosylated cationic glycopolymers for nucleic acid-mediated cancer immunotherapy,” UNITesi, Magazzini Digitali, 2019, 25 pages. (https://tesidottorato.depositolegale… [cited by applicant]
Chokhawala, Harshai A. et al., “Enzymatic Synthesis of Fluorinated Mechanistic Probes for Sialidases and Sialytransferases,” JACS Communications, 2007, vol. 129, pp. 10630-10631. [cited by applicant]
Definition of hemagglutinin [Influenza A virus (A/chicken/Jembrana/BPPV6/2004(H5N1))]. GenBank: ABE97562.1. https://www.ncbi.nlm.nih.gov/protein/ABE97562.1?report=genbank&log$=prottop&blast_rank=1&RID=CGUK0N57013. [cited by applicant]
Definition of hemagglutinin [Influenza A virus (A/Singapore/GP4444/2010(H1N1))]. GenBank: AEH59357.1. https://www.ncbi.nlm.nih.gov/protein/AEH59357.1?report=genbank&log$=prottop&blast_rank=1&RID=CGTA0JCD016. [cited by applicant]
Fan, CY et al., “Synthesis of Dendritic Cell-Targeted Polymeric Nanoparticles for Selective Delivery of mRNA Vaccines to Elicit Enhanced Immune Responses,” bioRxiv, Epub: Nov. 14, 2023; pp. 1-12; entire document; DOI: 1… [cited by applicant]
Huang, Han-Yi et al., “Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models,” Sci. Transl. Med., vol. 14, eabm0899, (2022), 13 pages. [cited by applicant]
Krammer, Florian et al., “Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies,” Journal of Virology, Jun. 2013, vol. 87, No. 12, pp. 6542-6550. [cited by applicant]
Wang, Shih-Chi et al., “Development of a universal influenza vaccine using hemagglutinin stem protein produced from Pichia pastoris,” Virology, 2019, vol. 526, pp. 125-137. [cited by applicant]
Yang et al., “Glucoproteomic Characterization of FUT8 Knock-Out Cells Reveals Roles of FUT8 in the Glycosylation,” Frontiers in Chemistry, Oct. 28, 2021, vol. 9, No. 755238, pp. 1-9, entire document. [cited by applicant]
Bang, Eun-Kyoung et al., JACS, 2013, vol. 135, pp. 2088-2091. dx.doi.org/10.1021/ja311961k. [cited by applicant]
Byrne et al., “CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation,” PLOS Biology, 2018, vol. 16, No. 8: e2005817. [cited by applicant]
Chuard, Nicolas et al., “Cell-penetrating poly(disulfide)s: the dependence of activity, depolymerization kinetics and intracellular localization on their length,” Organic & Biomolecular Chemistry, 2015, vol. 13, pp. 64-… [cited by applicant]
Ding, Li et al., “A [cited by applicant]
Engdahl, Cecilia et al., “Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postm… [cited by applicant]
Geisler, Christoph et al., “Engineering [beta]1,4-galactosyltransferase I to reduce secretion and enhance N-glycan elongation in insect cells,” Journal of Biotechnology, 2015, vol. 193, 52-65 (14 pages). [cited by applicant]
GenBank Accession NCBI No. QHD43416.1 (surface glycoprotein [Severe acute respiratory syndrome coronavirus 2]; published Mar. 18, 2020. [cited by applicant]
GenBank Accession No. nC_048600.1 ( [cited by applicant]
Gong, Yanqiu et al., “The glycosylation in SARS-CoV-2 and its receptor ACE2,” Signal Transduction and Targeted Therapy, 2021, vol. 6, 396 (24 pages). [cited by applicant]
Goswami, Roshan et al., “Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines,” Pharmaceutics, 2021, vol. 13, 240, 13 pages. [cited by applicant]
Grant, Oliver C. et al., “Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition,” Scientific Reports, 2020, vol. 10, 14991. https://doi.org/10.1038/s41598-020-71748-7. [cited by applicant]
Gutierrez Reyes, Cristian D., et al. “N-Glycome Profile of the Spike Protein S1: Systemic and Comparative Analysis from Eleven Variants of SARS-CoV-2,” Biomolecules, 2023, vol. 13, pp. 1421 (17 pages). [cited by applicant]
Hombu, Ryoma et al., “Cellular and Molecular Engineering of Glycan Sialylation in Heterologous Systems,” Molecules, 2021, vol. 26, 5950 (27 [ages). [cited by applicant]
Huang et al., “Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models,” Sci Transl Med., Apr. 6, 2022, vol. 14(639):eabm0899. [cited by applicant]
Levit, Mariia et al., “Bio-Inspired Amphiphilic Block-Copolymers Based on Synthetic Glycopolymer and Poly(Amino Acid) as Potential Drug Delivery Systems,” Polymers, 2020, vol. 12, pp. 183 (27 pages). doi:10.3390/polym12… [cited by applicant]
Pappalardo, Juan Sebastian et al., “Characterization of a Nanovaccine Platform Based on an [alpha]1,2-Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells,… [cited by applicant]
Shin et al., “CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome,” Nature Communications, 2017, vol. 8, Art. 15464. [cited by applicant]
Shivatare, Vidya et al., “Study on antibody Pc-glycosylation for optimal effector functions,” Chem Commun (Camb), 2024, vol. 59, iss. 37, pp. 5555-5558. doi:10.1039/d3cc00672g. [cited by applicant]
Wang, Ce et al., “Lymphatic-targeted cationic liposomes: A robust vaccine adjuvant for promoting long-term immunological memory,” Vaccine, 2014, vol. 32, 5475-5483. [cited by applicant]
Wang, Ce et al., Supplementary Data, 2014, Vaccine, 32, 5475-5483. [cited by applicant]
Wang, Qiong et al., “Antibody glycoengineering strategies in mammalian cells,” Biotechnology and Bioengineering, 2018, vol. 115:1378-1393. [cited by applicant]
Wu, Chung-Yi et al., “Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine,” PNAS, 2022, vol. 119, No. 9. https://doi.irg/10.1073/pnas.2119995119. [cited by applicant]
Zhang, Penghui et al., “Engineering the Surface of Smart Nanocarriers Using a pH-/Thermal-/GSH-Responsive Polymer Zipper for Precise Tumor Targeting Therapy in Vivo,” Advanced Materials, 2017, vol. 29, 1702311 (10 pages… [cited by applicant]
Zhang, Ruhe et al., “Poly(disulfide)s: From Synthesis to Drug Delivery,” Bio Macromolecules, 2022, vol. 23, pp. 1-19. [cited by applicant]
Zhang, Yong et al., “Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins,” Mol Cell Proteomics, 2021, vol. 20, 100058. https://doi.org/10.1074/mcp.RA120.002295. [cited by applicant]
Du, Dan et al., “The role of glucose transporters in the distribution of p-aminophenyl-[alpha]-D-mannopyranoside modified liposomes within mice brain,” Journal of Controlled Released, 2014, vol. 182. pp. 99-110. [cited by applicant]
He, P. et al., “Advances in aluminum hydroxide-based adjuvant research and its mechanism,” Human Vaccine and Immunotherapeutics, 2015, vol. 11, iss. 2, pp. 477-488. [cited by applicant]
Ma et al., “The Role of Glucose Transporters in the Distribution of p-aminophenyl mannppyranose modified liposomes within mice brains,” Journal of Controlled Release, 182, pp. 99-110. (Year: 2014). [cited by applicant]